A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).

被引：0
|
作者：
Okunaka, Mashiro
Furuoka, Momoka
Wakabayashi, Masashi
Furuya, Hideki
Bando, Hideaki
Shitara, Kohei
Nakayama, Izuma
机构：
[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Natl Canc Ctr Hosp East, Div Promot Drug & Diag Dev, Kashiwa, Japan
[4] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Japan
[5] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[6] Natl Canc Ctr Hosp East, Gastrointestinal Oncol Dept, Kashiwa, Japan
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.TPS504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS504 / TPS504
页数：1
相关论文
共 41 条
  • [1] Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials
    de Moraes, Francisco Cezar Aquino
    Pasqualotto, Eric
    Chavez, Matheus Pedrotti
    Ferreira, Rafael Oliva Morgado
    De Castria, Tiago Biachi
    Burbano, Rommel Mario Rodriguez
    BMC CANCER, 2024, 24 (01)
  • [2] Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials
    Francisco Cezar Aquino de Moraes
    Eric Pasqualotto
    Matheus Pedrotti Chavez
    Rafael Oliva Morgado Ferreira
    Tiago Biachi De Castria
    Rommel Mario Rodríguez Burbano
    BMC Cancer, 24
  • [3] Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
    Huang, Yufan
    You, Maojin
    Wu, Qundan
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [4] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-Hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Park, Jung Wook
    Oh, Mok
    Ajani, Jaffer A.
    LANCET, 2023, 401 (10389): : 1655 - 1668
  • [5] Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy
    Mehta, Rutika
    Shah, Manish A.
    ANNALS OF PALLIATIVE MEDICINE, 2022,
  • [6] Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas
    Shitara, Kohei
    Yamaguchi, Kensei
    Shoji, Hirokazu
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Park, Jung Wook
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)
    Shitara, K.
    Lordick, F.
    Bang, Y-J
    LANCET, 2023, 402 (10398): : 290 - 290
  • [8] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
  • [9] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Kosuke Morimoto
    Kensuke Moriwaki
    Kojiro Shimozuma
    Takeo Nakayama
    Journal of Gastroenterology, 2023, 58 : 1188 - 1197
  • [10] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
    Shen, Lin
    Zhang, Yanqiao
    Li, Ziyu
    Zhang, Xiaotian
    Gao, Xiangyu
    Liu, Bo
    Wang, Yusheng
    Ba, Yi
    Li, Ning
    Zhang, Ruixing
    Zhang, Jingdong
    Chen, Ye
    Chen, Jian
    Huang, Mingzhu
    Fu, Yang
    Liu, Mulin
    Liu, Zheng
    Zhao, Jun
    Li, Wei
    Wei, Jia
    Li, Changzheng
    Xu, Nong
    Guo, Zengqing
    Cao, Bangwei
    Liu, Lian
    Nie, Peng
    Wan, Lixin
    Sheng, Lili
    Liu, Zhenyang
    He, Yifu
    Gu, Kangsheng
    Wu, Guowu
    Wang, Weibo
    Zhang, Futong
    Qiu, Wensheng
    Guo, Jun
    Ying, Jieer
    Pan, Hongming
    Xu, Huiting
    Yuan, Yuan
    Bai, Yuansong
    Wang, Zhenghua
    Xu, Jiye
    Zhao, Xuehong
    Liu, Hao
    Zhang, Xizhi
    Dai, Wenxiang
    Xu, Hongyan
    Liu, Ming
    Xie, Lin
    NATURE MEDICINE, 2025, : 1163 - 1170
12345